Skip to main content
Erschienen in: Inflammation 6/2011

01.12.2011

Study of Programmed Cell Death 1 (PDCD1) Gene Polymorphims in Iranian Patients with Ankylosing Spondylitis

verfasst von: Narjes Soleimanifar, Ali Akbar Amirzargar, Mahdi Mahmoudi, Ali Akbar Pourfathollah, Esfandiar Azizi, Ahmad Reza Jamshidi, Nima Rezaei, Mohammad Taher Tahoori, Katayoon Bidad, Behrouz Nikbin, Mohammad Hossein Nicknam

Erschienen in: Inflammation | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

Ankylosing spondylitis (AS) is a chronic inflammatory disease, characterized by axial arthritis in which the genetic–environmental factors seem to be involved in the pathogenesis of the disease. This study was performed to investigate the role of polymorphisms of the programmed cell death 1 (PDCD1) gene on susceptibility to AS. In this study, 161 Iranian patients with AS and 208 normal controls were enrolled; two single-nucleotide polymorphisms (SNPs) of the PDCD1 gene PD-1.3 (G, A) in nucleotide position +7146 of intron 4 and PD-1.9 (C, T) in nucleotide +7625 of exon 5 were studied. Analysis of PD-1.3 revealed that 82% of patients and 79% of controls had GG genotype, while GA and AA genotypes were detected in 17% and 0.6% of patients, respectively, and 20% and 1.4% of controls, respectively. Moreover, the genotype CC (PD-1.9) was present in 92% of patients and 97% of controls. Although these differences were not statistically significant between patients and controls, comparisons of genotypes frequencies in the AS patients, based on human leukocyte antigen (HLA)-B27, revealed that all patients who had CT genotype (PD-1.9) were HLA-B27 positive, whereas 30% of patients with CC genotype were HLA-B27 negative. There was no evidence of association for PDCD1 SNPs with AS in our study, but CT genotype (PD-1.9) seems to be associated with HLA-B27 positivity in the patients with AS.
Literatur
1.
Zurück zum Zitat Goie The, H.S., M.M. Steven, S.M. van der Linden, and A. Cats. 1985. Evaluation of diagnostic criteria for ankylosing spondylitis: a comparison of the Rome, New York and modified New York criteria in patients with a positive clinical history screening test for ankylosing spondylitis. British Journal of Rheumatology 24: 242–249.PubMedCrossRef Goie The, H.S., M.M. Steven, S.M. van der Linden, and A. Cats. 1985. Evaluation of diagnostic criteria for ankylosing spondylitis: a comparison of the Rome, New York and modified New York criteria in patients with a positive clinical history screening test for ankylosing spondylitis. British Journal of Rheumatology 24: 242–249.PubMedCrossRef
2.
Zurück zum Zitat Brown, M.A. 2009. Genetics and the pathogenesis of ankylosing spondylitis. Current Opinion in Rheumatology 21: 318–323.PubMedCrossRef Brown, M.A. 2009. Genetics and the pathogenesis of ankylosing spondylitis. Current Opinion in Rheumatology 21: 318–323.PubMedCrossRef
3.
Zurück zum Zitat Lau, C.S., R. Burgos-Vargas, W. Louthrenoo, M.Y. Mok, P. Wordsworth, and Q.Y. Zeng. 1998. Features of spondyloarthritis around the world. Rheumatic Diseases Clinics of North America 24: 753–770.PubMedCrossRef Lau, C.S., R. Burgos-Vargas, W. Louthrenoo, M.Y. Mok, P. Wordsworth, and Q.Y. Zeng. 1998. Features of spondyloarthritis around the world. Rheumatic Diseases Clinics of North America 24: 753–770.PubMedCrossRef
4.
Zurück zum Zitat Reveille, J.D. 2009. Recent studies on the genetic basis of ankylosing spondylitis. Current Rheumatology Reports 11: 340–348.PubMedCrossRef Reveille, J.D. 2009. Recent studies on the genetic basis of ankylosing spondylitis. Current Rheumatology Reports 11: 340–348.PubMedCrossRef
5.
Zurück zum Zitat Okazaki, T., and T. Honjo. 2006. The PD-1-PD-L pathway in immunological tolerance. Trends in Immunology 27: 195–201.PubMedCrossRef Okazaki, T., and T. Honjo. 2006. The PD-1-PD-L pathway in immunological tolerance. Trends in Immunology 27: 195–201.PubMedCrossRef
6.
Zurück zum Zitat Gunal, E.K., F.O. Sarvan, S. Kamali, A. Gul, M. Inanc, M. Carin, M. Konice, O. Aral, and L. Ocal. 2008. Low frequency of HLA-B27 in ankylosing spondylitis patients from Turkey. Joint, Bone, Spine 75: 299–302.PubMedCrossRef Gunal, E.K., F.O. Sarvan, S. Kamali, A. Gul, M. Inanc, M. Carin, M. Konice, O. Aral, and L. Ocal. 2008. Low frequency of HLA-B27 in ankylosing spondylitis patients from Turkey. Joint, Bone, Spine 75: 299–302.PubMedCrossRef
7.
Zurück zum Zitat Alaez, C., E. Gazit, B. Ibarrola, M. Yaron, A. Livneh, O. Avishai, and C. Gorodezky. 2007. Distribution of HLA-B27 subtypes in ankylosing spondylitis in an Israeli population. Archives of Medical Research 38: 452–455.PubMedCrossRef Alaez, C., E. Gazit, B. Ibarrola, M. Yaron, A. Livneh, O. Avishai, and C. Gorodezky. 2007. Distribution of HLA-B27 subtypes in ankylosing spondylitis in an Israeli population. Archives of Medical Research 38: 452–455.PubMedCrossRef
8.
Zurück zum Zitat Nicknam, M.H., M. Mahmoudi, A.A. Amirzargar, M. Ganjalikhani Hakemi, F. Khosravi, A.R. Jamshidi, A. Amirkhani, B. Ansaripour, Z. Pourpak, M. Moin, and B. Nikbin. 2008. Determination of HLA-B27 subtypes in Iranian patients with ankylosing spondylitis. Iranian Journal of Allergy, Asthma, and Immunology 7: 19–24.PubMed Nicknam, M.H., M. Mahmoudi, A.A. Amirzargar, M. Ganjalikhani Hakemi, F. Khosravi, A.R. Jamshidi, A. Amirkhani, B. Ansaripour, Z. Pourpak, M. Moin, and B. Nikbin. 2008. Determination of HLA-B27 subtypes in Iranian patients with ankylosing spondylitis. Iranian Journal of Allergy, Asthma, and Immunology 7: 19–24.PubMed
9.
Zurück zum Zitat Azizi, E., A. Massoud, A.A. Amirzargar, M. Mahmoudi, N. Soleimanifar, N. Rezaei, A.R. Jamshidi, B. Nikbin, and M.H. Nicknam. 2010. Association of CTLA4 gene polymorphism in Iranian patients with ankylosing spondylitis. Journal of Clinical Immunology 30: 268–271.PubMedCrossRef Azizi, E., A. Massoud, A.A. Amirzargar, M. Mahmoudi, N. Soleimanifar, N. Rezaei, A.R. Jamshidi, B. Nikbin, and M.H. Nicknam. 2010. Association of CTLA4 gene polymorphism in Iranian patients with ankylosing spondylitis. Journal of Clinical Immunology 30: 268–271.PubMedCrossRef
10.
Zurück zum Zitat Nicknam, M.H., M. Mahmoudi, A.A. Amirzargar, A.R. Jamshidi, N. Rezaei, and B. Nikbin. 2009. HLA-B27 subtypes and tumor necrosis factor alpha promoter region polymorphism in Iranian patients with ankylosing spondylitis. European Cytokine Network 20: 17–20.PubMed Nicknam, M.H., M. Mahmoudi, A.A. Amirzargar, A.R. Jamshidi, N. Rezaei, and B. Nikbin. 2009. HLA-B27 subtypes and tumor necrosis factor alpha promoter region polymorphism in Iranian patients with ankylosing spondylitis. European Cytokine Network 20: 17–20.PubMed
11.
Zurück zum Zitat Okazaki, T., and T. Honjo. 2007. PD-1 and PD-1 ligands: from discovery to clinical application. International Immunology 19: 813–824.PubMedCrossRef Okazaki, T., and T. Honjo. 2007. PD-1 and PD-1 ligands: from discovery to clinical application. International Immunology 19: 813–824.PubMedCrossRef
12.
Zurück zum Zitat Keir, M.E., L.M. Francisco, and A.H. Sharpe. 2007. PD-1 and its ligands in T-cell immunity. Current Opinion in Immunology 19: 309–314.PubMedCrossRef Keir, M.E., L.M. Francisco, and A.H. Sharpe. 2007. PD-1 and its ligands in T-cell immunity. Current Opinion in Immunology 19: 309–314.PubMedCrossRef
13.
Zurück zum Zitat Sharpe, A.H., E.J. Wherry, R. Ahmed, and G.J. Freeman. 2007. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nature Immunology 8: 239–245.PubMedCrossRef Sharpe, A.H., E.J. Wherry, R. Ahmed, and G.J. Freeman. 2007. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nature Immunology 8: 239–245.PubMedCrossRef
14.
Zurück zum Zitat Okazaki, T., and J. Wang. 2005. PD-1/PD-L pathway and autoimmunity. Autoimmunity 38: 353–357.PubMedCrossRef Okazaki, T., and J. Wang. 2005. PD-1/PD-L pathway and autoimmunity. Autoimmunity 38: 353–357.PubMedCrossRef
15.
Zurück zum Zitat Zhu, B., I. Guleria, A. Khosroshahi, T. Chitnis, J. Imitola, M. Azuma, H. Yagita, M.H. Sayegh, and S.J. Khoury. 2006. Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis. Journal of Immunology 176: 3480–3489. Zhu, B., I. Guleria, A. Khosroshahi, T. Chitnis, J. Imitola, M. Azuma, H. Yagita, M.H. Sayegh, and S.J. Khoury. 2006. Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis. Journal of Immunology 176: 3480–3489.
16.
Zurück zum Zitat Thorburn, C.M., L. Prokunina-Olsson, K.A. Sterba, R.F. Lum, M.F. Seldin, M.E. Alarcon-Riquelme, and L.A. Criswell. 2007. Association of PDCD1 genetic variation with risk and clinical manifestations of systemic lupus erythematosus in a multiethnic cohort. Genes and Immunity 8: 279–287.PubMedCrossRef Thorburn, C.M., L. Prokunina-Olsson, K.A. Sterba, R.F. Lum, M.F. Seldin, M.E. Alarcon-Riquelme, and L.A. Criswell. 2007. Association of PDCD1 genetic variation with risk and clinical manifestations of systemic lupus erythematosus in a multiethnic cohort. Genes and Immunity 8: 279–287.PubMedCrossRef
17.
Zurück zum Zitat Velazquez-Cruz, R., L. Orozco, F. Espinosa-Rosales, R. Carreno-Manjarrez, E. Solis-Vallejo, N.D. Lopez-Lara, I.K. Ruiz-Lopez, A.L. Rodriguez-Lozano, J.K. Estrada-Gil, G. Jimenez-Sanchez, and V. Baca. 2007. Association of PDCD1 polymorphisms with childhood-onset systemic lupus erythematosus. European Journal of Human Genetics 15: 336–341.PubMedCrossRef Velazquez-Cruz, R., L. Orozco, F. Espinosa-Rosales, R. Carreno-Manjarrez, E. Solis-Vallejo, N.D. Lopez-Lara, I.K. Ruiz-Lopez, A.L. Rodriguez-Lozano, J.K. Estrada-Gil, G. Jimenez-Sanchez, and V. Baca. 2007. Association of PDCD1 polymorphisms with childhood-onset systemic lupus erythematosus. European Journal of Human Genetics 15: 336–341.PubMedCrossRef
18.
Zurück zum Zitat Bertsias, G.K., M. Nakou, C. Choulaki, A. Raptopoulou, E. Papadimitraki, G. Goulielmos, H. Kritikos, P. Sidiropoulos, M. Tzardi, D. Kardassis, C. Mamalaki, and D.T. Boumpas. 2009. Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. Arthritis and Rheumatism 60: 207–218.PubMedCrossRef Bertsias, G.K., M. Nakou, C. Choulaki, A. Raptopoulou, E. Papadimitraki, G. Goulielmos, H. Kritikos, P. Sidiropoulos, M. Tzardi, D. Kardassis, C. Mamalaki, and D.T. Boumpas. 2009. Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. Arthritis and Rheumatism 60: 207–218.PubMedCrossRef
19.
Zurück zum Zitat Kong, E.K., L. Prokunina-Olsson, W.H. Wong, C.S. Lau, T.M. Chan, M. Alarcon-Riquelme, and Y.L. Lau. 2005. A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese. Arthritis and Rheumatism 52: 1058–1062.PubMedCrossRef Kong, E.K., L. Prokunina-Olsson, W.H. Wong, C.S. Lau, T.M. Chan, M. Alarcon-Riquelme, and Y.L. Lau. 2005. A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese. Arthritis and Rheumatism 52: 1058–1062.PubMedCrossRef
20.
Zurück zum Zitat Wang, S.C., C.H. Lin, R.N. Li, T.T. Ou, C.C. Wu, W.C. Tsai, H.W. Liu, and J.H. Yen. 2007. Polymorphisms of genes for programmed cell death 1 ligands in patients with rheumatoid arthritis. Journal of Clinical Immunology 27: 563–567.PubMedCrossRef Wang, S.C., C.H. Lin, R.N. Li, T.T. Ou, C.C. Wu, W.C. Tsai, H.W. Liu, and J.H. Yen. 2007. Polymorphisms of genes for programmed cell death 1 ligands in patients with rheumatoid arthritis. Journal of Clinical Immunology 27: 563–567.PubMedCrossRef
21.
Zurück zum Zitat Nielsen, C., D. Hansen, S. Husby, B.B. Jacobsen, and S.T. Lillevang. 2003. Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. Tissue Antigens 62: 492–497.PubMedCrossRef Nielsen, C., D. Hansen, S. Husby, B.B. Jacobsen, and S.T. Lillevang. 2003. Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. Tissue Antigens 62: 492–497.PubMedCrossRef
22.
Zurück zum Zitat Kroner, A., M. Mehling, B. Hemmer, P. Rieckmann, K.V. Toyka, M. Maurer, and H. Wiendl. 2005. A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Annals of Neurology 58: 50–57.PubMedCrossRef Kroner, A., M. Mehling, B. Hemmer, P. Rieckmann, K.V. Toyka, M. Maurer, and H. Wiendl. 2005. A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Annals of Neurology 58: 50–57.PubMedCrossRef
23.
Zurück zum Zitat Lee, S.H., Y.A. Lee, D.H. Woo, R. Song, E.K. Park, M.H. Ryu, Y.H. Kim, K.S. Kim, S.J. Hong, M.C. Yoo, and H.I. Yang. 2006. Association of the programmed cell death 1 (PDCD1) gene polymorphism with ankylosing spondylitis in the Korean population. Arthritis Research & Therapy 8: R163.CrossRef Lee, S.H., Y.A. Lee, D.H. Woo, R. Song, E.K. Park, M.H. Ryu, Y.H. Kim, K.S. Kim, S.J. Hong, M.C. Yoo, and H.I. Yang. 2006. Association of the programmed cell death 1 (PDCD1) gene polymorphism with ankylosing spondylitis in the Korean population. Arthritis Research & Therapy 8: R163.CrossRef
25.
Zurück zum Zitat Prokunina, L., C. Castillejo-Lopez, F. Oberg, I. Gunnarsson, L. Berg, V. Magnusson, A.J. Brookes, D. Tentler, H. Kristjansdottir, G. Grondal, A.I. Bolstad, E. Svenungsson, I. Lundberg, G. Sturfelt, A. Jonssen, L. Truedsson, G. Lima, J. Alcocer-Varela, R. Jonsson, U.B. Gyllensten, J.B. Harley, D. Alarcon-Segovia, K. Steinsson, and M.E. Alarcon-Riquelme. 2002. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nature Genetics 32: 666–669.PubMedCrossRef Prokunina, L., C. Castillejo-Lopez, F. Oberg, I. Gunnarsson, L. Berg, V. Magnusson, A.J. Brookes, D. Tentler, H. Kristjansdottir, G. Grondal, A.I. Bolstad, E. Svenungsson, I. Lundberg, G. Sturfelt, A. Jonssen, L. Truedsson, G. Lima, J. Alcocer-Varela, R. Jonsson, U.B. Gyllensten, J.B. Harley, D. Alarcon-Segovia, K. Steinsson, and M.E. Alarcon-Riquelme. 2002. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nature Genetics 32: 666–669.PubMedCrossRef
26.
Zurück zum Zitat Prokunina, L., L. Padyukov, A. Bennet, U. de Faire, B. Wiman, J. Prince, L. Alfredsson, L. Klareskog, and M. Alarcon-Riquelme. 2004. Association of the PD-1.3A allele of the PDCD1 gene in patients with rheumatoid arthritis negative for rheumatoid factor and the shared epitope. Arthritis and Rheumatism 50: 1770–1773.PubMedCrossRef Prokunina, L., L. Padyukov, A. Bennet, U. de Faire, B. Wiman, J. Prince, L. Alfredsson, L. Klareskog, and M. Alarcon-Riquelme. 2004. Association of the PD-1.3A allele of the PDCD1 gene in patients with rheumatoid arthritis negative for rheumatoid factor and the shared epitope. Arthritis and Rheumatism 50: 1770–1773.PubMedCrossRef
27.
Zurück zum Zitat Liu, X., L.H. Hu, Y.R. Li, F.H. Chen, Y. Ning, and Q.F. Yao. 2009. Programmed cell death 1 gene polymorphisms is associated with ankylosing spondylitis in Chinese Han population. Rheumatology International. doi:10.1007/s00296-009-1264-1. Liu, X., L.H. Hu, Y.R. Li, F.H. Chen, Y. Ning, and Q.F. Yao. 2009. Programmed cell death 1 gene polymorphisms is associated with ankylosing spondylitis in Chinese Han population. Rheumatology International. doi:10.​1007/​s00296-009-1264-1.
28.
Zurück zum Zitat Liu, J.L., F.Y. Zhang, Y.H. Liang, F.L. Xiao, S.Q. Zhang, Y.L. Cheng, C.D. Yuan, Q.P. Chen, S. Yang, and X.J. Zhang. 2009. Association between the PD1.3A/G polymorphism of the PDCD1 gene and systemic lupus erythematosus in European populations: a meta-analysis. Journal of the European Academy of Dermatology and Venereology 23: 425–432.PubMedCrossRef Liu, J.L., F.Y. Zhang, Y.H. Liang, F.L. Xiao, S.Q. Zhang, Y.L. Cheng, C.D. Yuan, Q.P. Chen, S. Yang, and X.J. Zhang. 2009. Association between the PD1.3A/G polymorphism of the PDCD1 gene and systemic lupus erythematosus in European populations: a meta-analysis. Journal of the European Academy of Dermatology and Venereology 23: 425–432.PubMedCrossRef
29.
Zurück zum Zitat Lin, S.C., J.H. Yen, J.J. Tsai, W.C. Tsai, T.T. Ou, H.W. Liu, and C.J. Chen. 2004. Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus. Arthritis and Rheumatism 50: 770–775.PubMedCrossRef Lin, S.C., J.H. Yen, J.J. Tsai, W.C. Tsai, T.T. Ou, H.W. Liu, and C.J. Chen. 2004. Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus. Arthritis and Rheumatism 50: 770–775.PubMedCrossRef
Metadaten
Titel
Study of Programmed Cell Death 1 (PDCD1) Gene Polymorphims in Iranian Patients with Ankylosing Spondylitis
verfasst von
Narjes Soleimanifar
Ali Akbar Amirzargar
Mahdi Mahmoudi
Ali Akbar Pourfathollah
Esfandiar Azizi
Ahmad Reza Jamshidi
Nima Rezaei
Mohammad Taher Tahoori
Katayoon Bidad
Behrouz Nikbin
Mohammad Hossein Nicknam
Publikationsdatum
01.12.2011
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 6/2011
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-010-9282-4

Weitere Artikel der Ausgabe 6/2011

Inflammation 6/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.